{"id":1926,"date":"2017-03-01T12:17:07","date_gmt":"2017-03-01T12:17:07","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=1926"},"modified":"2021-10-12T08:45:01","modified_gmt":"2021-10-12T03:15:01","slug":"hepatitis-c-drugs-re-energize-global-fight-over-patents","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/hepatitis-c-drugs-re-energize-global-fight-over-patents","title":{"rendered":"Hepatitis C drugs re-energize global fight over patents"},"content":{"rendered":"

The liver disease hepatitis C is the new battleground for lawsuits intended to slash the cost of life-saving medicines. In February alone, five suits were filed in India and Argentina claiming that the latest class of antiviral drugs does not warrant the 20-year patent monopoly that manufacturers have sought in those countries. Roughly 177.5 million adults worldwide are infected with the hepatitis C virus, which can cause liver cancer and cirrhosis if left untreated \u2014 but the latest antiviral medications have revolutionized care. The first to reach the market was sofosbuvir, sold under the name Sovaldi by Gilead Sciences of Foster City, California; clinical trials of the drug in combination with other medications have shown a cure rate of 95% or more.\u00a0Four of the lawsuits filed in February target Indian patents on sofosbuvir and two related drugs, Gilead\u2019s velpatasvir (sold in combination with sofosbuvir under the name Epclusa) and Daklinza (daclatasvir) from Bristol-Myers Squibb in New York City. The fifth challenges Gilead\u2019s application to patent sofosbuvir in Argentina. Some of the suits argue that sofosbuvir, velpatasvir and daclatasvir are not sufficiently inventive to warrant a patent. Others challenge Gilead\u2019s attempts to obtain additional patents on sofosbuvir by modifying it slightly, to extend the company\u2019s intellectual-property rights \u2014 a practice called evergreening.<\/p>\n

To know more, click Hepatitis C Drugs<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"

The liver disease hepatitis C is the new battleground for lawsuits intended to slash the cost of life-saving medicines. In February alone, five suits were filed in India and Argentina claiming that the latest class of antiviral drugs does not warrant the 20-year patent monopoly that manufacturers have sought in those countries. Roughly 177.5 million […]<\/p>\n","protected":false},"author":1,"featured_media":1927,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[794,288,1394,17471,321,793,712],"industry":[17225],"therapeutic_areas":[17231],"class_list":["post-1926","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-gilead","tag-hepatitis","tag-hepatitis-c","tag-hepatitis-c-drugs","tag-indian-pharma-industry","tag-patent-fight","tag-pharma-industry","industry-pharmaceutical","therapeutic_areas-infectious-diseases"],"acf":[],"yoast_head":"\nHepatitis C Market | Hepatitis C Pipeline | DelveInsight<\/title>\n<meta name=\"description\" content=\"The liver disease hepatitis C is the new battleground for lawsuits intended to slash the cost of life-saving medicines. In February alone, five suits\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/hepatitis-c-drugs-re-energize-global-fight-over-patents\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hepatitis C Market | Hepatitis C Pipeline | DelveInsight\" \/>\n<meta property=\"og:description\" content=\"The liver disease hepatitis C is the new battleground for lawsuits intended to slash the cost of life-saving medicines. In February alone, five suits\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/hepatitis-c-drugs-re-energize-global-fight-over-patents\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-03-01T12:17:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-10-12T03:15:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/03\/09021347\/patent.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"959\" \/>\n\t<meta property=\"og:image:height\" content=\"639\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hepatitis C Market | Hepatitis C Pipeline | DelveInsight","description":"The liver disease hepatitis C is the new battleground for lawsuits intended to slash the cost of life-saving medicines. In February alone, five suits","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/hepatitis-c-drugs-re-energize-global-fight-over-patents","og_locale":"en_US","og_type":"article","og_title":"Hepatitis C Market | Hepatitis C Pipeline | DelveInsight","og_description":"The liver disease hepatitis C is the new battleground for lawsuits intended to slash the cost of life-saving medicines. In February alone, five suits","og_url":"https:\/\/www.delveinsight.com\/blog\/hepatitis-c-drugs-re-energize-global-fight-over-patents","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-03-01T12:17:07+00:00","article_modified_time":"2021-10-12T03:15:01+00:00","og_image":[{"width":959,"height":639,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/03\/09021347\/patent.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/hepatitis-c-drugs-re-energize-global-fight-over-patents","url":"https:\/\/www.delveinsight.com\/blog\/hepatitis-c-drugs-re-energize-global-fight-over-patents","name":"Hepatitis C Market | Hepatitis C Pipeline | DelveInsight","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/hepatitis-c-drugs-re-energize-global-fight-over-patents#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/hepatitis-c-drugs-re-energize-global-fight-over-patents#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/03\/09021347\/patent.jpg","datePublished":"2017-03-01T12:17:07+00:00","dateModified":"2021-10-12T03:15:01+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The liver disease hepatitis C is the new battleground for lawsuits intended to slash the cost of life-saving medicines. In February alone, five suits","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/hepatitis-c-drugs-re-energize-global-fight-over-patents"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/hepatitis-c-drugs-re-energize-global-fight-over-patents#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/03\/09021347\/patent.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/03\/09021347\/patent.jpg","width":959,"height":639},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/03\/09021347\/patent-300x200.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Gilead<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">hepatitis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">hepatitis c<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Hepatitis C Drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Indian pharma industry<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Patent Fight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Pharma Industry<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Gilead<\/span>","<span class=\"advgb-post-tax-term\">hepatitis<\/span>","<span class=\"advgb-post-tax-term\">hepatitis c<\/span>","<span class=\"advgb-post-tax-term\">Hepatitis C Drugs<\/span>","<span class=\"advgb-post-tax-term\">Indian pharma industry<\/span>","<span class=\"advgb-post-tax-term\">Patent Fight<\/span>","<span class=\"advgb-post-tax-term\">Pharma Industry<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Mar 1, 2017","modified":"Updated on Oct 12, 2021"},"absolute_dates_time":{"created":"Posted on Mar 1, 2017 12:17 pm","modified":"Updated on Oct 12, 2021 8:45 am"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1926","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=1926"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/1926\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1927"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=1926"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=1926"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=1926"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=1926"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=1926"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}